Phase II Trial, Open Label, Single-arm, of Immune Checkpoint Inhibitor In High Risk Oral Premalignant Lesions
Latest Information Update: 03 Apr 2024
At a glance
- Drugs Avelumab (Primary)
- Indications Mouth disorders; Precancerous conditions
- Focus Therapeutic Use
- Acronyms IMPEDE
- 06 Jun 2023 Interim safety results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 27 Nov 2020 Status changed from not yet recruiting to recruiting.
- 10 Aug 2020 New trial record